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Molecular targeted therapies are based upon drugs acting on tumors by interfering
with specific targets involved in growth and spread of cancer. Many targeted therapies
were approved by Food and Drug Administration as standard treatment, others were
introduced into preclinical or clinical studies on hematological malignancies (HMs). The
development of drug-resistance in some HMs and the lack of effective treatments in
other ones emphasized the need for searching new molecular targets and therapeutic
agents. The aim of this study was to evaluate the effects of 4c pyrazolo[3,4-d]
pyrimidine compound, a Src inhibitor, on lymphoid and myeloid neoplasms. Here, we
demonstrated its ability to reduce cell viability, induce apoptosis and cell cycle arrest in
lymphoid cell lines such as Jurkat, SKMM1, Derl-2/7, and myeloid cell lines, such as
Jurl-MK1. Moreover, we reported a high expression of a Src kinase, Fyn, in these cell
lines compared to healthy subjects. This study was a starting point to investigate 4c
pyrazolo[3,4-d]pyrimidine compound as a drug for HMs and Src kinases as its potential
molecular targets.
Keywords: targeted therapies, Src kinase inhibitor, pyrazolo[3, 4-d]pyrimidine compound, Fyn tyrosine kinase,
hematological malignancies
INTRODUTION
Targeted cancer therapies are “drugs” designed to interfere with specific molecules necessary for
tumor growth and progression. These agents are broadly classified in monoclonal antibodies and
small molecules. The first are generally directed against antigens expressed on neoplastic cell
surface, the second are usually designed to interfere with the enzymatic activity of the target
protein. A primary goal of these kind of therapies is to fight cancer cells with more precision while
to do less damage to normal cells.
The approval of imatinib mesylate for the treatment of chronic myeloid leukemia (CML) and its
high success rate supported the extensive efforts to develop novel molecularly targeted therapies for
hematologic malignancies (Cierpicki and Grembecka, 2015). On the other hand, the development
of drug-resistance in some hematological tumors, for example in CML (An et al., 2010), and the
lack of effective treatments in other ones (Martelli et al., 2012; Yang and Lin, 2015; Zinzani et al.,
2015), addressed researchers to the study of new molecular targets and innovative therapeutic
agents.
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A lot of new compounds have been synthesized, investigated,
and introduced into pre-clinical and clinical studies in
hematological malignancies (HMs; Korycka-Wołowiec et al.,
2015). The majority of small molecule block activity of protein
kinases, including FMS-like tyrosine kinase 3 (FLT3; Levis, 2013;
Plawny and Rie, 2014), Aurora kinase (Garcia-Manero et al.,
2015), JAK1/2 (Pinilla-Ibarz et al., 2016), Akt, mTOR (Cierpicki
and Grembecka, 2015) and Src kinases (Roskoski, 2015b).
The Src family protein tyrosine kinases (SFKs) are non-
receptor intracellular kinases known to have diverse and
important regulatory roles in both normal hematopoiesis and
leukemogenesis. There are eight members of this family in
mammals and they are structurally related, except for the unique
domain: Src, Lyn, Hck, Fyn, Yes, Blk, Fgr, and Lck (Ku et al.,
2015). SFKs represent appealing targets for cancer therapy
because of their aberrant activation in many human cancer
types and their key role in controlling several processes, such
as proliferation, apoptosis, migration, and angiogenesis, whose
deregulation underlies cancer development and progression
(Yeatman, 2004).
Recently we synthesized new pyrazolo[3,4-d]pyrimidine
library of SFKs inhibitors, which entered in ATP binding site
and showed antiproliferative and pro-apoptotic action in several
tumor types such as CML and in Burkitt lymphoma (Schenone
et al., 2010; Cozzi et al., 2012; Radi et al., 2013; Tintori et al., 2013).
Moreover, we demonstrated that 4c pyrazolo[3,4-d]pyrimidine
compound was able to reduce cell viability, induce apoptosis and
cell cycle arrest in a rare natural killer (NK) cell leukemia and in
CML. In particular, it reduced phosphorylation of Fyn kinase in
these neoplasms (Tintori et al., 2015; Laurenzana et al., 2016).
Fyn kinase is able to interact with several proteins and
participates in different cellular pathways, both in physiological
and pathological situations. It has been demonstrated that
it is involved in the regulation of T-cell development and
activation, factor and cytokine receptor signaling, cell–cell
adhesion, integrin-mediated signaling, ion channel function,
platelet activation, T- and B-cell receptor signaling, axon
guidance, mitosis, differentiation of NK cells (Palacios and Weiss,
2004; Salmond et al., 2009; Saito et al., 2010).
The aim of this study was to analyze the effects of 4c
compound on viability of cell lines derived from different
lymphoid and myeloid neoplasms and to report Fyn expression
analysis in these tumors compared to healthy subjects.
MATERIALS AND METHODS
Cell Lines and Chemical
Peripheral blood samples were obtained from healthy donors
(HDs). The study was approved by the Ethics Committee of
IRCCS-CROB (Prot. 3725; 07/02/2008) and all subjects gave
informed consent according to the Declaration of Helsinki.
Peripheral blood mononuclear cells from HDs (HD-PBMCs)
were isolated by Ficoll-hypaque gradient separation.
Both human lymphoid and myeloid cell lines were purchased
from Leibniz-Institut DSMZ – Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH or from American
Type Culture Collection and cultured as follows. Jurkat (acute
T cell leukemia), Derl-2 and Derl-7 (T cell lymphoma), NALM-
6 and BV173 (acute lymphoblastic leukemia), Jurl-MK1 (CML),
NB4 and HL-60 (acute promyelocytic leukemia), Kasumi-1
(acute myeloid leukemia) cell lines were cultured in RPMI 1640
(Gibco, Life technologies, Carlsbad, CA, USA) supplemented
with 20% fetal bovine serum (FBS, Gibco) and 1% of penicillin-
streptomycin (pen/strep, Gibco). For Derl-2 and Derl-7, 20 ng/ml
interleukin-2 (IL-2, Miltenyi Biotec, Auburn, CA, USA) was
added at the previous indicated medium. OCI-AML3 cell
line (acute myeloid leukemia) was cultured in Dulbecco’s
Modified Eagle Medium (DMEM, Gibco) supplemented with
20% FBS, 1% of pen/strep. SKMM1 cells (multiple myeloma)
were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM,
Gibco) supplemented with 10% FBS, 1% of pen/strep. All cell
lines were maintained in incubator at 37◦C and 5% CO2.
4c pyrazolo[3,4-d]pyrimidine compound, given by Lead
Discovery Siena s.r.l. (patent: WO2016066755), was dissolved in
dimethyl sulfoxide (DMSO, Sigma-Aldrich, St Louis, MO, USA)
and diluted in FBS for cell treatments.
Western Blotting (WB) Analysis
Cells were lysed as previously reported (Trino et al., 2016).
Sixty micrograms was subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis on a 10% gel under reducing
conditions and then electrotransferred onto a polyvinylidene
difluoride membranes using Trans Blot Turbo Transfer System
(BioRad, Hercules, CA, USA). Membranes were probed with
primary antibodies directed against Fyn and β-actin (Cell
Signaling, Beverly, MA, USA), then incubated with secondary
antibody (horseradish peroxidase-conjugated goat anti-mouse or
anti-rabbit; Cell Signaling). Immune complexes were detected
by ECL chemiluminescence system (Bio-Rad Laboratories),
as recommended by the manufacturer. Densitometric analysis
was performed using Bio-Rad Image Lab 4.1 software. The
intensity of bands of all proteins was normalized to the β-actin
signal.
Cell Viability
All cell lines were seeded into 96-well plates (3× 104 cells/100 µl)
and incubated with 4c compound at increasing concentrations
(1, 5, 10, 15 µM). HD-PBMCs were incubated with 15 µM
of 4c compound. Treatment was carried out for 24, 48, and
72 h. Cells treated with DMSO vehicle were used as control.
Cell viability was determined using the CellTiter 96 Aqueous
One Solution assay kit (MTS, Promega, Madison, WI, USA). The
optical density was measured at 492 nm. Cellular viability was
calculated as percentage of viable cells compared with control.
All experiments were conducted in triplicate. EC50 values were
obtained by GraphPad Prism (GraphPad Prism, San Diego, CA,
USA).
Functional Tests
Cells were seeded at 3 × 105 cells/ml cell density. Jurkat were
treated with 2 µM of 4c compound for 24, 48, and 72 h; Derl-2
and Derl-7 with 4 µM of 4c compound for 72 h; while Jurl-MK1
with 1 µM of 4c compound for 72 h. All cell lines were incubated
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with DMSO vehicle as control. After 4c compound treatment
cells were used in:
Apoptosis Assay
Apoptosis was evaluated by cytometric analysis of Annexin
V and Propidium Iodide (PI)-stained cells using fluorescein
isothiocyanate (FITC) Annexin V Apoptosis Detection kit I (BD)
as previously reported (De Luca et al., 2016). Cells were acquired
using FACSCalibur flow cytometer and analyzed by CellQuest
Pro software (BD). Single positive for Annexin V and double
positive for Annexin V and PI cells were interpreted as signs of
early and late phases of apoptosis, respectively.
Cell Cycle Analysis
After treatment cells were fixed in cold ethanol 70% for 1 h, then
labeled with PI/RNase staining solution for 30 min. Samples were
acquired by FACSCalibur (BD). Data were analyzed by ModFit
LT Software (Verity Software House).
Statistical Analysis
Statistical significance was determined using a paired t-test by
GraphPad Prism. All error bars represent standard deviation




Reduced Cell Viability in Hematological
Malignancies
We treated 3 HD-PBMCs, 6 lymphoid and 5 myeloid cell lines
(Table 1) with 4c pyrazolo[3-4,d]pyrimidine compound or with
DMSO vehicle control at increasing concentrations (1–15 µM)
from 24 to 72 h to verify its effect on cell viability.
First of all, we observed that 4c compound had negligible
effect on HD-PBMCs at 15 µM in a time course, from 24 to
72 h (Figure 1A). In the context of lymphoid malignancies
(Figure 1B), Jurkat, SKMM1 and Derl-2 cell lines showed a wide
reduction of cell viability (about −50%) already at 5 µM and it
increased at higher concentrations of 4c compound, reaching a
reduction of cell viability of 60–70% at 10 µM. This effect was
observed at 24 h and remained constant at other time points.
Derl-7 and BV-173 showed a dose-dependent viability reduction
after treatment with 4c compound with the higher effect at 48
and 72 h, −25 and −60% at 15 µM, respectively. On NALM-6
cell line, we observed a reduction of viability of 40% at 15 µM of
4c compound at all time points.
In the context of myeloid malignancies (Figure 1C), Jurl-MK1
and NB-4 showed a dose-dependent reduction of viability after 4c
compound treatment, especially at 48 and 72 h.
HL-60 and OCI-AML3 showed 20 and 30% reduction of
cell viability, respectively, after 15 µM 4c treatment at all time
points. Kasumi-1 showed a decrease of viability at increasing
concentration of 4c compound at all time points; the reduction
of 50% was observed at 15 µM at 48 and 72 h.
TABLE 1 | Hematological malignancies (HM) cell lines analyzed.
Cell lines Disease
Lymphoid Neoplasms Jurkat Acute T cell leukemia
SKMM1 Multiple myeloma
Derl-2 T cell lymphoma
Derl-7 T cell lymphoma
BV-173 Acute lymphoblastic leukemia
NALM-6 Acute lymphoblastic leukemia
Myeloid Neoplasms Jurl-MK1 Chronic myeloid leukemia
NB-4 Acute promyelocytic leukemia
HL-60 Acute promyelocytic leukemia
OCI-AML3 Acute myeloid leukemia
Kasumi-1 Acute myeloid leukemia
We calculated 4c compound EC50 values for all cell lines at
24, 48, and 72 h (Table 2). For lymphoid neoplasms, Jurkat cells
showed EC50 around 4 µM at 24, 48, and 72 h; SKMM1showed
EC50 = 7.7 µM at 24 h which increased at 48 and 72 h; Derl-
2, Derl-7 and BV-173 showed a decrease of EC50 values over
time. For NALM-6 EC50 value was much greater than the highest
concentration used. For myeloid malignancies, Jurl-MK1 showed
EC50 > 15 µM at 24 h but it considerably decreased at 2.5 µM at
48 and 72 h. The same trend was observed in NB-4 cells, in which
EC50 was >15 µM at 24 h and it decreased at 48 and 72 h at 7.2
and 5.9µM, respectively. HL-60 and OCI-AML3 had EC50 higher
than 15 µM at all time points. Kasumi-1 showed EC50 = 15 µM
at 48 and 72 h.
4c Pyrazolo[3,4-d]pyrimidine Compound
Increased Apoptosis in Jurkat, Derl-2,
Derl-7, and Jurl-MK1 Cells
To further investigate cell death mechanism induced after
treatment, we performed apoptosis on Jurkat, Derl-2, Derl-7,
and Jurl-MK1 cell lines by cytometric analysis of Annexin V/PI
(Figure 2). Jurkat cells were treated with 2 µM of 4c compound
for 24, 48, and 72 h. After treatment we observed a significant
increase of apoptotic cells at all time points respect to their
control, 34% at 24 h, 18% at 48 h, and 27% at 72 h (p< 0.01). The
treatment with 4 µM of 4c compound for 72 h on Derl-2 and
Derl-7 induced an increased apoptosis respect to their control
(40% p < 0.05 and 23% p < 0.01, respectively). Jurl-MK1 cells,
after incubation with 1 µM of 4c compound for 72 h, showed an
increased apoptosis rate respect to control (18%; p< 0.05).
4c Pyrazolo[3,4-d]pyrimidine Compound
Induced Cell Cycle Arrest in Jurkat,
Derl-2, Derl-7, and Jurl-MK1 Cells
We also performed cell cycle analysis on Jurkat, Derl-2, Derl-7,
and Jurl-MK1 cell lines by cytometric analysis of PI (Figure 3).
Jurkat were treated with 2 µM of 4c compound for 24, 48, and
72 h; Derl-2 and Derl-7 with 4 µM of 4c at for 72 h; while
Jurl-MK1 with 1 µM of 4c compound for 72 h. Jurkat showed
cell cycle arrest in G0/G1 phase in all time points, especially
at 24 h, respect to control. Derl-2 displayed a strong arrest in
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FIGURE 1 | Cell viability assay after 4c compound treatment in hematological malignancies. Viability of three healthy donors-peripheral blood mononuclear
cells (HD-PBMCs) (A), six lymphoid (B), and five myeloid (C) cell lines was evaluated by MTS assay after treatment with 4c compound at different concentration (1,
5, 10, and 15 µM) for 24, 48, and 72 h. Results are expressed as percent of cell viability normalized to DMSO-treated control cells. The bar-graphs represent mean
with SD from three independent experiments.
TABLE 2 | EC50 values calculated in Healthy donors-peripheral blood
mononuclear cells (HD-PBMCs) and in both lymphoid and myeloid cell
lines after 4c compound treatment.
Cells EC50 [µM]
24 h 48 h 72 h
HD-PBMCs >15 >15 >15
Lymphoid Neoplasms Jurkat 4.6 4 3.8
SKMM1 7.7 8.11 10.8
Derl-2 7.5 5.9 6.2
Derl-7 12.3 4.7 4.7
BV-173 >15 6.6 7.15
NALM-6 >15 >15 >15
Myeloid Neoplasms Jurl-MK1 >15 2.5 2.4
NB-4 >15 7.2 5.9
HL-60 >15 >15 >15
OCI-AML3 >15 >15 >15
Kasumi-1 >15 15 15
G0/G1 phase, whereas Derl-7 manifested a negligible effect on cell
cycle after treatment, respect to control. Jurl-MK1 showed a small
increase of G0/G1 phase and a larger raise of percent of cells in S
phase.
Fyn Is Over-Expressed in Hematological
Malignancies
We analyzed Fyn protein expression in 3 HD-PBMCs, in
lymphoid and myeloid cell lines by WB analysis. Fyn is
over-expressed in lymphoid cell lines respect to HD-PBMCs;
in particular, SKMM1 showed the major amount of protein,
following by NALM-6, Derl-7, Jurkat, Derl-2, and BV-173. Also
all myeloid Jurl-MK1, NB-4, OCI-AML3, and Kasumi-1 cells
presented higher Fyn protein expression (Figure 4).
DISCUSSION
“Molecular targeted therapies” are used in the treatment of many
cancers as first-line therapy (Neul et al., 2016). The first tyrosine
kinase inhibitor (TKI) approved for the treatment of CML was
imatinib mesylate (Cierpicki and Grembecka, 2015). Since then,
over 3000 novel agents inhibiting diverse protein kinases are
currently being explored preclinically and, at present, more than
130 novel TKIs are being evaluated in oncological clinical trials
(Neul et al., 2016).
Recent studies on tumor pathobiology in hematological
and solid cancers have revealed that heterogeneity is the
major cause of poor drug efficacy and response duration
(Visvader, 2011; McGranahan and Swanton, 2015; Belizário
et al., 2016). Moreover, cancer cells that respond to particularly
therapeutic treatment can rapidly adapt and develop drug-
resistance changing their signaling pathways (Luo et al., 2009;
Carragher et al., 2012; McGranahan and Swanton, 2015; Belizário
et al., 2016). At this point comes the need to screen new molecular
targets and innovative therapeutic agents.
Protein kinases, including SFKs, are the most attractive
target structures. They are key players in signal transduction
networks mediating fundamental cellular processes such as
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FIGURE 2 | Apoptosis analysis in hematological malignancies after 4c compound treatment. Apoptosis was evaluated by flow cytometer in Jurkat cell line
after 4c compound or DMSO vehicle treatment at 2 µM for 24, 48, and 72 h; in Derl-2 and Derl-7 after treatment at 4 µM for 72 h; in Jurl-MK1 after treatment at
1 µM for 72 h. Dot plots show a single representative experiment, the bar-graphs represent mean with SD from three independent experiments. ∗ and ∗∗ indicated a
P-value minor than 0.05 and 0.01, respectively.
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FIGURE 3 | Cell cycle analysis in hematological malignancies after 4c compound treatment. Cell cycle analysis was evaluated by flow cytometer in Jurkat
cell line after 4c compound or DMSO vehicle treatment at 2 µM for 24, 48, and 72 h; in Derl-2 and Derl-7 after treatment at 4 µM for 72 h; in Jurl-MK1 after
treatment at 1 µM for 72 h. Histogram plots show a single representative experiment, the bar-graphs represent mean with SD from three independent experiments.
cell differentiation, proliferation, apoptosis, transcription,
metabolism, and intercellular communication. During the past
15 years, was emerged that many cancers originated from
dysregulation of their signaling pathways (Manning et al., 2002;
Levitzki, 2013; Rask-Andersen et al., 2014; Roskoski, 2015a)
and drug development has shifted toward small molecules that
specifically block them.
In this context, our group developed a library of
pyrazolo[3,4-d]pyrimidine compounds which have the ability
to inhibit some of Src kinases by entering in the ATP binding
site. In particular, we have previously demonstrated that 4c
pyrazolo[3,4-d]pyrimidine compound, is able to inhibit Fyn
kinase and to induce apoptosis in cells derived from NK leukemia
and from CML (Tintori et al., 2015; Laurenzana et al., 2016).
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FIGURE 4 | Fyn expression in different hematological malignant cells. Western Blotting (WB) analysis of Fyn levels in 3 HD-PBMCs compared to lymphoid cell
lines (A) and in three HD-PBMCs compared to myeloid cell lines (B). Quantification of Fyn protein levels was normalized with β-actin bands. The bar-graphs
represent mean with SD from three independent experiments.
In this study, we demonstrated, for the first time, the cytotoxic
effect of 4c compound on HMs compared with HD-PBMCs.
First, we investigated the response of cell viability to 4c
compound treatment. We have recently demonstrated that 4c
compound, up to 10 µM, had no effect on HD-PBMCs cell
viability at 24, 48, and 72 h (Laurenzana et al., 2016). In this
study, we confirmed these data and observed that also 15 µM of
4c compound had no effect on viability of HD-PBMCs at all time
points.
Interestingly, Jurkat, SKMM1, Derl-2, Derl-7, and BV-173
showed a dose-dependent reduction of cell viability and their
EC50 values were in a range of 3–10 µM at all time points.
Derl-2 and Derl-7 were established from the same patient with
hepatosplenic γδ T cell lymphoma, but they showed a different
phenotype: Derl-2 was TcRγδ+, while Derl-7 was TcRγδ− (Di
Noto et al., 2001). Derl-2, closer to T cells, showed a lower
EC50 at 24 h. Within lymphoid cell lines, NALM-6 showed a
lower response to 4c treatment and a reduction of 50% of cell
viability at higher concentrations respect to other cells. BV-173
and NALM-6 derived both from acute lymphoblastic leukemia
but showed different response to 4c compound, probably due
to the clinical and biological heterogeneity of this neoplasm.
BV-173, for example, expressed Philadelphia (Ph) chromosome,
lacking instead in NALM-6. In the context of myeloid cell lines,
we observed an EC50 achievement at concentration≤15µM at 48
and 72 h for Jurl-MK1, NB-4, and Kasumi-1 cell lines. Jurl-MK1
response could be comparable to lymphoid BV-173 cells probably
due to the presence of Ph chromosome in both cell lines.
In general, lymphoid cells seemed to respond better than
myeloid ones. In agreement with our data, a lot of recent
studies showed that the use of TKIs, especially against Btk, Syk,
and Lyn, is a promising new strategy for targeted treatment
of B-cell lymphoid malignancies (Robak and Robak, 2012).
Furthermore, these data on Jurl-MK1 confirmed our previously
results obtained in K562 CML cell line (Tintori et al., 2015).
We decided to study in deep the viability reduction in Jurkat,
Derl-2, Derl-7, and Jurl-MK1 cell lines and we demonstrated that
4c compound induced apoptosis and cell cycle arrest.
Recent studies showed that other small molecules induced cell
viability reduction and apoptosis in cell lines used in our study.
For example, Bucur et al. (2015) synthesized a small molecule that
binds caspase 8 and enhances its activation when combined with
TRAIL inducing apoptosis in Jurkat cells. Furthermore, Lin et al.
(2010) demonstrated that SMI-4a, a small molecule inhibitor of
Pim kinases, kill a wide range of both myeloid and lymphoid cell
lines with precursor T-cell lymphoblastic leukemia/lymphoma
being highly sensitive.
Since we previously observed, by in vitro enzymatic assay,
that 4c compound inhibited different Src kinases, in particular
Fyn with IC50 = 0.07 µM (Tintori et al., 2015), we verified the
presence of Fyn protein in our HM cell lines. Interestingly, we
observed that its expression is higher and variable in all cell lines
compared to HD-PBMCs.
Fyn, a member of SFKs, has diverse molecular functions,
including regulation of cell growth, survival, adhesion,
cytoskeletal remodeling, motility, axon guidance, synaptic
function, platelet activation, and T cell receptor signaling. It is
involved in various aspects of the pathogenesis of different types
of cancers as well as drug resistance (Elias and Ditzel, 2015) so it
could be a potential therapeutic target.
In a rare NK leukemia, we demonstrated that antiproliferative
activity of 4c compound was due to Fyn kinase inhibition
(Laurenzana et al., 2016). Recently, Palomero et al. (2014)
demonstrated that dasatinib, a multikinase inhibitor which blocks
ABL1 and SRC kinases, induced dose dependent inhibition of
FYN phosphorylation.
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Our preliminary data indicated Fyn as a potential target of
4c compound but cannot be excluded that 4c compound might
also act on other Src kinases activated in neoplastic cells. Other
experiments are needed to evaluate this hypothesis.
In summary, in this study we demonstrated that 4c
pyrazolo[3,4-d]pyrimidine compound had cytotoxic effect by
inducing a reduction of cell viability and a increased apoptosis in
different cell lines derived from HMs. Finally, we observed that
4c compound potential target, Fyn kinase, is over-expressed in all
cell lines used. But others experiments are necessary in this fields,
because this study represents a starting point to better investigate
the effect of 4c pyrazolo[3,4-d]pyrimidine compound and the role
of Src kinases in HMs.
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